Table 3 Mean (CI 95%) and analysis of variance (ANOVA) of baseline. 1 and 5Â week Patient-Reported Outcomes
Self-Reported Outcomes | T2: 1Â week Evaluation | T3: 5Â week Evaluation | ||||
|---|---|---|---|---|---|---|
|  | Experimental (n = 20) | Control (n = 20) | ANOVA F(p) | Experimental (n = 20) | Control (n = 20) | ANOVA F(p) |
POMS | ||||||
 Tension/Anxiety | 6.05 (3.26–8.83) | 6.50 (3.52–9.47) | 0.05 (0.81) | 5.40 (2.77–8.02) | 6.50 (3.89–9.10) | 0.38 (0.53) |
 Depression/Dejection | 8.00 (3.76–12.23) | 10.05 (5.26–14.83) | 0.45 (0.50) | 6.35 (2.71–9.98) | 9.30 (4.41–14.19) | 1.02 (0.31) |
 Anger/Hostility | 5.40 (3.20–7.59) | 5.75 (2.51–8.98) | 0.03 (0.85) | 4.25 (2.51–5.98) | 6.60 (2.69–10.50) | 1.32 (0.25) |
 Vigor/Activity | 24.80 (20.46–29.13) | 26.70 (23.13–30.26) | 0.50 (0.48) | 28.10 (24.09–32.10) | 25.90 (21.85–29.94) | 0.65 (0.42) |
 Fatigue/Inertia | 8.85 (6.49–11.20) | 8.75 (6.56–10.93) | 0.004 (0.94) | 6.40 (4.33–8.46) | 8.00 (5.76–10.23) | 1.21 (0.27) |
 Confusion/Bewilderment | 5.95 (3.10–8.79) | 7.10 (3.52–10.67) | 0.27 (0.60) | 3.75 (0.84–6.65) | 5.00 (1.55–8.44) | 0.33 (0.56) |
 TMD | 109.90 (97.14–122.66) | 111. 30 (95.33–127.27) | 0.02 (0.88) | 98.05 (85.33–110.77) | 109.40 (93.87–124.93) | 1.40 (0.24) |
EORTC QLQ-C30 | ||||||
 Global health status/QoL | 67.49 (59.50–75.48) | 63.74 (56.55–70.93) | 0.53 (0.47) | 76.66 (69.66–83.66) | 62.91 (56.15–69.66) | 8.75 (0.005) |
Functional scales | ||||||
 Physical functioning | 78.68 (69.12–88.24) | 74.03 (62.34–85.71) | 0.41 (0.52) | 80.18 (69.45–90.90) | 75.03 (63.70–86.35) | 0.47 (0.49) |
 Role functioning | 85.83 (73.88–97.77) | 70.83 (54.85–86.81) | 2.47 (0.12) | 91.66 (82.71–100.61) | 79.16 (68.76–89.56) | 3.63 (0.06) |
 Emotional functioning | 83.78 (75.36–92.20) | 77.96 (65.83–90.09) | 0.68 (0.41) | 85.90 (78.35–93.45) | 81.36 (71.89–90.83) | 0.61 (0.43) |
 Cognitive functioning | 91.76 (82.02–101.30) | 84.99 (73.42–96.56) | 0.85 (0.36) | 92.49 (84.70–100.28) | 84.16 (72.71–95.61) | 1.58 (0.21) |
 Social functioning | 87.49 (74.87–100.12) | 86.66 (75.46–97.86) | 0.01 (0.91) | 91.66 (81.70–101.63) | 94.99 (89.28–100.71) | 0.36 (0.54) |
Symptoms scales | ||||||
 Fatigue | 26.62 (18.62–34.61) | 37.76 (28.16–47.37) | 3.48 (0.07) | 21.62 (12.46–30.78) | 39.42 (28.55–50.30) | 6.87 (0.01) |
 Nausea and vomiting | 0.00 (0.00–0.00) | 0.83 (−0.91–2.57) | 1.00 (0.32) | 1.66 (− 0.73–4.06) | 0.00 (0.00–0.00) | 2.11 (0.15) |
 Pain | 29.16 (17.88–40.44) | 31.66 (20.37–42.95) | 0.10 (0.74) | 19.99 (10.00–29.94) | 34.16 (24.20–44.11) | 4.41 (0.04) |
 Dyspnoea | 5.00 (−5.46–15.46) | 8.33 (− 2.84–19.50) | 0.20 (0.65) | 3.33 (− 3.64–10.30) | 4.99 (− 2.63–12.63) | 0.11 (0.73) |
 Insomnia | 29.99 (14.89–45.09) | 29.99 (14.89–45.09) | 0.00 (1.00) | 23.33 (9.84–36.81) | 23.33 (8.92–37.73) | 0.00 (1.00) |
 Appetite loss | 11.66 (1.20–22.12) | 18.33 (1.95–34.71) | 0.51 (0.47) | 11.66 (1.20–22.12) | 14.99 (3.15–26.84) | 0.19 (0.66) |
 Constipation | 1.66 (−1.82–5.15) | 9.99 (−0.24–20.24) | 2.59 (0.11) | 1.66 (−1.82–5.15) | 6.66 (−2.93–16.26) | 1.04 (0.31) |
 Diarrhoea | 8.33 (−0.24–16.91) | 4.99 (−2.63–12.63) | 0.36 (0.54) | 3.33 (− 1.46–8.13) | 8.33 (− 0.24–16.91) | 1.13 (0.29) |
 Financial difficulties | 3.33 (3.64–10.30) | 8.33 (− 1.63–18.29) | 0.74 (0.39) | 3.33 (− 3.64–10.30) | 4.99 (− 2.63–12.63) | 0.11 (0.73) |
 VAS | 6.10 (5.44–6.76) | 6.15 (5.26–7.04) | 0.009 (0.92) | 4.90 (4.03–5.77) | 6.45 (5.65–7.25) | 7.56 (0.009) |
 SFI | 67.20 (60.36–74.03) | 59.80 (53.77–65.82) | 2.88 (0.09) | 66.80 (57.08–76.51) | 59.20 (53.41–64.98) | 1.97 (0.16) |
 ULFI | 72.60 (65.38–79.81) | 72.20 (67.36–77.03) | 0.009 (0.92) | 72.40 (62.64–82.15) | 70.60 (64.36–76.83) | 0.10 (0.74) |
 BAI | 0.42 (0.32–0.51) | 0.44 (0.31–0.57) | 0.11 (0.73) | 0.33 (0.24–0.43) | 0.40 (0.27–0.56) | 0.83 (0.36) |
 MBS | 0.19 (0.59–0.32) | 0.33 (0.19–0.46) | 2.46 (0.12) | 0.17 (0.05–0.28) | 0.33 (0.18–0.47) | 3.23 (0.08) |
 BADIX | 0.35 (0.25–0.45) | 0.42 (0.30–0.54) | 0.84 (0.36) | 0.28 (0.19–0.37) | 0.39 (0.26–0.51) | 2.16 (0.14) |